Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years- A Non-interventional Observational Study
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms KRONOS
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 12 Sep 2023 Status changed from not yet recruiting to recruiting.
- 11 Jul 2023 Planned initiation date changed from 31 May 2023 to 30 Jul 2023.
- 27 Mar 2023 New trial record